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Abstract
The role of contaminated preservation fluid in the development of infection after liver trans-
plantation has not been fully elucidated. To assess the incidence and etiology of contami-
nated preservation fluid and determine its impact on the subsequent development of
infection after liver transplantation, we prospectively studied 50 consecutive liver trans-
plants, and cultured the following samples in each instance: preservation fluid (immediately
before and at the end of the back-table procedure, and just before implantation), blood, and
bile from the donor, and ascitic fluid from the recipient. When any culture was positive,
blood cultures were obtained and targeted antimicrobial therapy was started. We found that
the incidence of contaminated preservation fluid was 92% (46 of 50 cases of liver transplan-
tation per year), but only 28% (14/50) were contaminated by recognized pathogens. Blood
and bile cultures from the donor were positive in 28% and 6% respectively, whereas ascitic
fluid was positive in 22%. The most frequently isolated microorganisms were coagulase-
negative staphylococci. In nine cases, the microorganisms isolated from the preservation
fluid concurred with those grown from the donor blood cultures, and in one case, the isolate
matched with the one obtained from bile culture. No liver transplant recipient developed an
infection due to the transmission of an organism isolated from the preservation fluid. Our
findings indicate that contamination of the preservation fluid is frequent in liver transplanta-
tion, and it is mainly caused by saprophytic skin flora. Transmission of infection is low, par-
ticularly among those recipients given targeted antimicrobial treatment for organisms
isolated in the preservation fluid.
Introduction
Liver transplantation has become the definitive treatment of several end-stage liver diseases
[1–3]. In recent years, with the growing disparity between organ availability and the number of
candidates for liver transplantation, most centers have extended the acceptance criteria for
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donors [4,5]. However, this strategy increases the risk of bacterial, viral, and fungal infections
after transplantation [6,7], making post-transplant infection a leading cause of in-hospital
mortality among liver transplant recipients [8–10].
Contamination of preservation fluid has been identified as a potential source of post-trans-
plant infection [6,11], although the reported incidence ranges from as low as 9.5% to as high as
98.4% [7,12–14]. The frequency of infection transmitted via the preservation fluid varies
depending on the type of the study [6,13]. Moreover, related case-fatality rates have been
reported to exceed 50%, depending on the causative organisms [13]. However, our current
understanding of the contamination of preservation fluid and subsequent recipient infection
derives to a large extent from retrospective studies in which only a few fluids from patients
were examined.
To detect allograft contamination and improve the early diagnosis and approach of infec-
tion-related complications, some transplant centers now routinely take intra-operative cultures
of organ preservation fluid. However, evidence supporting this practice is scarce, and little is
known about the most appropriate management strategy for liver recipients with confirmed
preservation fluid contamination. In this study, we aimed to clarify the incidence and etiology
of preservation fluid contamination in liver transplantation to determine the role of this con-
tamination in the subsequent development of infection.
Materials and Methods
We conducted a prospective observational study at a tertiary university referral hospital for
adults in Barcelona, Spain, where some 50 liver transplants are performed annually. For this
study, we included all liver transplants from September 2012 to August 2013, collecting demo-
graphic and medical information from the donors and the recipients (including immunosup-
pressive treatment, occurrence of acute allograft rejection, infections, clinical features,
microbiologic studies, and outcomes) as well as the operative data. All data were carefully
recorded in a database. Differences in donor, baseline, and surgical characteristics of those
undergoing liver transplantation were evaluated.
None of the transplant donors were from a vulnerable population and all donors or next of
kin provided written informed consent that was freely given. Written informed consent was
considered not necessary for the study, as it was an analysis of our usual everyday work. The
data of the patients were anonymized for the purposes of this analysis. The confidential infor-
mation of the patients was protected according national normative. This manuscript was
approved for its publication by the Clinical Research Ethics Committee of Bellvitge University
Hospital.
The microbiology reports for all the positive cultures (blood and preservation fluid) were
reviewed daily by the infectious disease team, and patients were then followed up by an infec-
tious disease physician. When pathogens were isolated from donor or preservation fluids,
blood cultures were taken from the recipient and targeted antimicrobial therapy was pre-
scribed. However, treatment was stopped if no clinical signs of infection developed or if cul-
tures from the recipient were negative.
Grafts were routinely preserved in Celsior solution at 4°C. The liver was placed in a sterile
plastic double-bag and transported in a third non-sterile bag. Back-table procedures were per-
formed in a separate dedicated room near to where the organ retrieval was performed.
In order to detect the exact time when the PF is contaminated, and to understand which is
the main mechanism involved in the contamination, three samples of preservation fluid were
routinely obtained under sterile conditions (immediately before the back-table procedure, at
the end of the back-table procedure, and just before implantation). Under sterile conditions,
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we also systematically obtained blood and bile samples from donors and ascites samples from
recipients.
Preservation fluid contamination during the back-table procedure was defined as isolation
of any organism from the sample obtained after the back-table procedure, but not in the sample
recovered before the back-table procedure. Contamination of the preservation fluid during
liver transplantation was defined as isolation of any organism from the sample obtained just
before the graft implantation, but not recovered from the sample obtained before the back-
table procedure.
Infections were defined according to the CDC/NHSN guidelines [15]. In case of infection
after liver transplantation, the source of infection was determined by clinical criteria and isola-
tion of any organism from a clinically significant site of infection. When no sites were identi-
fied, infection was considered to be from a primary or unknown source.
Prior transplantation referred to re-transplantation of the same organ. Empirical antibiotic
therapy was considered inadequate if the treatment regimen did not include at least one antibi-
otic with in vitro activity against the infecting microorganism. Shock was defined as a systolic
blood pressure of less than 90 mmHg, which was unresponsive to fluid treatment or required
vasoactive drug therapy [16]. Acute allograft rejection was diagnosed only when proven by
biopsy. The overall case-fatality rate was defined as death by any cause within the first 30 days
of the onset of infection.
All patients received perioperative antibacterial prophylaxis with teicoplanin plus aztreo-
nam for up to 24 hours after transplantation. Antifungal prophylaxis was given to high-risk
recipients according to current recommendations [17]. Prophylaxis against Pneumocystis jiro-
veci infection was with trimethoprim–sulfamethoxazole given as a single dose, three times a
week, for the first 6 months after transplantation. Prophylaxis against cytomegalovirus (CMV)
was given according to the current guidelines [18].
Samples were processed by the BACTEC 9240 method (Becton-Dickinson Microbiology Sys-
tems, Sparks, MD). The inoculated bottles were incubated for five days at 35°C before being dis-
charged. Microbial identification was performed using commercially available panels (MicroScan
[Siemens; West Sacramento, United States] or Vitek [Biomérieux; Marcy-L’Étoile, France]), by
standard biochemical and/or enzymatic test, or by matrix-assisted laser desorption ionization
(MALDI-TOF; Bruker Daltonik; Bremen, Germany). The Clinical and Laboratory Standards
(CLSI) criteria were used to define susceptibility or resistance to antimicrobial agents. Antibiotic
susceptibility was tested using the micro-dilution method, following CLSI guidelines [19].
The microbiologic results of the preservation fluid culture were compared to the results of
samples from the donor and the recipient. The criteria for microorganism matching were
based on species identification and susceptibility profiles.
The statistical analysis was performed using PASW Statistics for Windows, Version 18.0
(SPSS, Inc., Chicago, IL, USA). Categorical variables were characterized by percentages and
compared with chi-square tests, while continuous variables were expressed as means and stan-
dard deviations, or as medians and interquartile ranges (IQR), according to their distribution.
Comparisons were made using the Mann- Whitney U test. All statistical tests were two-tailed
and the threshold of statistical significance was<0.05.
Results
We recorded the details of 50 consecutive liver transplantation among 47 patients during the
study period. Table 1 shows the baseline characteristics for the liver donors and liver recipients,
including the operation-related data. The median age of liver recipients was 57 (IQR 52–62)
years, and 82% were male. The most frequent indication for liver transplantation was
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hepatocellular carcinoma, followed by chronic hepatitis C and alcoholic cirrhosis. The median
age of donors was 63 (IQR 51–69) years, and 64% were male. Two were domino transplants, but
the remaining forty-eight were deceased-donor transplants. Causes of death of donors were
stroke (35), head trauma (8), cerebral anoxia (4), and other (1). The median time of ischemia was
377 (IQR 310–480) minutes, and the median time of surgery was 385 (IQR 344–450) minutes.
The microorganisms isolated are detailed in full in Table 2. All cultures of the preservation
fluids collected before the back-table procedure were negative. One or more microorganisms
were isolated in the preservation fluids collected just before implantation in 46 out of 50 trans-
plants, representing an incidence rate of 92% for contamination of the preservation fluid. In
eight cases the contamination was polymicrobial, and in 14 cases (28%) the isolates were con-
sidered pathogens. Blood samples and bile samples were positive in 14 (28%) and three donors
(6%) respectively, and ascites samples were positive in 11 out of 50 recipients (22%); but only
two isolates were considered pathogens in each setting. In nine cases, isolates from the preser-
vation fluid were consistent with those isolated in blood cultures from the donor; these were
coagulase-negative staphylococci in seven cases, and streptococci viridans and candida spp. in
one case each. In another case, the preservation fluid isolate (Enterobacter spp.) matched that
obtained from the bile culture. S1 File links information about each recipient and their donor,
as well as the operative features characteristics and the microorganisms isolated in each case.
Table 3 shows data of liver recipients with contaminated preservation fluid before implanta-
tion regarding microorganisms involved, susceptibility to antibiotic prophylaxis, treatment and
Table 1. Baseline liver donor and recipient characteristics, and operation features characteristics.
CHARACTERISTICS N = 50
Donor features
Age, median (IQR) 63 (51–69)
Weight (Kg), median (IQR) 80 (72–90)
Height (m), median (IQR) 1.7 (1.65–1.8)
Male sex, no. (%) 32 (64)
Heart disease, no. (%) 13 (26)
Length of ICU stay, median (IQR) 2 (1–6)
Operative features
Cold ischemia time (minutes), median (IQR) 377 (310–480)
Length of surgery (minutes), median (IQR) 385 (344–450)
Red blood cell transfusion, no. (%) 29 (58)
Fresh-frozen plasma transfusion, no. (%) 15 (30)
Platelets transfusion, no. (%) 27 (54)
Recipient features
Age, median (IQR) 57 (52–62)
Male sex, no. (%) 41 (82)
HTA pre-LT, no. (%) 13 (26)
DM pre-LT, no. (%) 9 (18)
MELD, median (IQR) 20 (15–25)
Length of ICU stay post-LT (days), median (IQR) 3 (2–4)
Length of hospitalization post-LT (days), median (IQR) 12 (9–20)
Infection during the ﬁrst month post-LT, no. (%) 6 (12)
Overall case-fatality rate, no. (%) 1 (2)
IQR: Interquartile range; ICU: Intensive Care Unit; HTA: arterial hypertension; DM: Diabetes mellitus; LT:
liver transplantation; MELD: Model of End-Stage Liver Disease
doi:10.1371/journal.pone.0160701.t001
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outcomes. The median duration of targeted antibiotic treatment, for those liver recipients with
contaminated preservation fluid, was 6 (IQR 4.8–7.5) days.
During the study period, only six recipients suffered infections during the first month after
liver transplantation, although none of these was due to possible pathogen transmission from
the donor to the recipient. Three recipients required re-transplantation for ischemic cholangi-
tis, acute cellular graft rejection, and hepatic artery thrombosis. One recipient died because of
an acute hepatic artery thrombosis.
Finally, we compared various donor and surgical features as well as the outcomes between
liver recipients with and without the growth of pathogens in the preservation fluid culture col-
lected just before implantation. Table 4 summarizes the results of the between-group compari-
son. No statistical differences were found.
Discussion
In this prospective study of 50 consecutive liver transplants, the incidence of preservation fluid con-
tamination was 92% just before implantation. True pathogenic contamination accounted for 28%.
Despite this high incidence, however, we did not identify any cases of infectious transmission.
Previous studies have reported a wide variability in the incidence of preservation fluid con-
tamination [7,12–14], which may be due to the fact that some reports define contamination as
the positive growth of any microorganism, while others require the isolation of known human
pathogens [20,21]. In addition, the time of collection of samples during the process of liver
transplantation, and the sensitivity of culture methods, differ among the published studies
[6,22]. At present, little is known about the clinical value of collecting and culturing the preser-
vation fluid, or about the appropriate management of recipients with positive cultures from
preservation fluid samples.
Table 2. Microorganisms isolated in the preservation fluid, blood, and bile samples from the donor and in the ascites samples from the recipients.
Microorganisms PF-1a PF -2b PF -3c Biled Bloode Ascitesf
CNS - 8 32 1 10 7
S. pneumoniae - 1 1 - - -
MSSA - - 5 - - -
Enterobacter spp. - - 3 1 - -
Escherichia coli - - 1 - - 1
Serratia spp. - - 1 - - -
Enterococcus faecium - - 2 - - 1
Enterococcus faecalis - - 2 - - 1
Other streptococci spp. - 1 6 - 1 -
Haemophilus spp. - - - 1 1 -
Klebsiella pneumoniae - - - - 1 -
Bacillus spp. - - 1 1 - 1
Corynebacterium spp. - 1 1 - - -
Candida spp. - - 1 - 1 -
CNS, Coagulase-negative staphylococci; MSSA, methicillin-sensitive Staphylococcus aureus; PF, preservation ﬂuid; LT, Liver transplantation.
a PF-1: Preservation ﬂuid collected before the back-table procedure
b PF-2: Preservation ﬂuid at the end of the back-table procedure
c PF-3: Preservation ﬂuid collected just before implantation
d Bile: bile sample from the donor
e Blood: Blood sample from the donor
f Ascites: Ascites sample from the recipient.
doi:10.1371/journal.pone.0160701.t002
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Given that the prevalence of preservation fluid contamination was high, it is reasonable to
speculate that the lack of infection transmission is related to the use of early, targeted antimi-
crobial treatment. However, we identified matches between isolates in the preservation fluid
and isolates in the blood and bile cultures of donors, suggesting that this is a plausible route of
infection transmission. It should be noted, however, that we did not perform a molecular epi-
demiology analysis, which would be necessary to confirm that these were truly the same
microorganisms.
Few reports in the literature have shown the transmission of infection from donor to recipi-
ent through preservation fluid contamination [6,13,23,24]. When reported, the mortality rate
in cases of infectious transmission is high [13,25]. Moreover, the scarce literature available sug-
gests that transmission via the contamination of the preservation fluid is always related to
known human pathogens. In the absence of data to the contrary, we should probably consider
recipients at risk if these pathogens grow in preservation fluid cultures.
We collected preservation fluid samples at different times during the transplant procedure
in an attempt to detect when preservation fluid was contaminated. In this regard, our findings
concurred with those found by previous researchers who suggested that preservation fluid is
most frequently contaminated during harvesting and manipulation in the back-table procedure
[7]. Indeed, in the present study, all preservation fluid cultures before the back-table procedure
were negative, while 92% of that collected just before implantation grew microorganisms.
Table 3. Liver recipients with contaminated preservation fluid before implantation: microorganisms involved, susceptibility to antimicrobial pro-
phylaxis, treatment and outcomes.
Case Organisms isolated in
the PF
AAP AP Treatment Days of
treatment
Length of
ICU stay
(days)
LOS
(days)
Infection1 Re-
transplantation
Death
1 Serratia spp Yes Yes Ertapenem 4 3 9 No No No
2 Enterococcus faecalis
Streptococcus viridans
CNS
Yes Yes Meropenem 6 2 26 Cholangitis and E.
faecium
bacteremia
Ischemic
cholangitis
No
3 Enterococcus faecium
CNS
Yes Yes Linezolid 15 2 12 No No No
4 Enterobacter cloacae
Bacillus cereus
No No Ciproﬂoxacin 4 3 8 No No No
5 Staphylococcus aureus Yes No Cefazolin 6 3 19 No No No
6 Enterobacter cloacae
Enterococcus faecalis
No No Amoxicillin
+ Ciproﬂoxacin
7 3 12 No No No
7 Staphylococcus aureus Yes No Teicoplanin/
Daptomycin
6 2 12 No No No
8 Staphylococcus aureus
Streptococcus sanguis
Yes No Aztreonam
+ Teicoplanin
5 4 12 No No No
9 Enterobacter aerogenes Yes No Ertapenem 10 8 34 No No No
10 Staphylococcus aureus
Enterococcus faecium
Yes No Linezolid 9 10 23 No No No
11 Streptococcus
pneumoniae
Yes No Ceftriaxone 4 2 7 No No No
12 Staphylococcus aureus Yes No Daptomycin 5 2 8 No No No
13 Escherichia coli Yes Yes Ceftriaxone 7 10 37 No No No
14 Candida glabrata CNS No No Anidulafungin 7 2 10 No No No
Abbreviations: AAP, adequate antibiotic prophylaxis; AP, antifungal prophylaxis; CNS, Coagulase-negative staphylococci; ICU, Intensive Care Unit; LOS,
Length of hospitalization post-LT; N, no; PF, preservation ﬂuid; Y, yes
1 Infection during the ﬁrst month post-LT
doi:10.1371/journal.pone.0160701.t003
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Moreover, the most frequently isolated microorganisms were superficial saprophytic flora,
which could have occurred at any of a number of stages during the transplantation process,
including the multiple-step procedures and the packaging of the liver after removal from the
donor. Our data indicate that the most appropriate time to culture preservation fluids would
be just before implantation and that taking other samples is probably of limited clinical value.
Among the strengths of this study are the prospective design and that we included a large
number of different samples collected at different points during the transplant process, finding
that contamination varies according to the time of samples. However, it should be acknowl-
edged that our study has some limitations. For example, this was a single center study; in addi-
tion, due to the small size of our series, it was not possible to compare the differences between
positive and negative cultures to identify risk factors for preservation fluid contamination.
Conclusions
Preservation fluid contamination is frequent during liver transplantation, and it is mainly
caused by superficial saprophytic flora. Transmission of infection is low among those recipients
given targeted antimicrobial treatment for organisms isolated in the preservation fluid. How-
ever, prospective multicenter studies, which should include molecular epidemiological analy-
ses, are required to determine the optimal strategies for the prevention and management of
subsequent infection.
Supporting Information
S1 File. Liver donor and recipient characteristics, operation features characteristics and
microorganisms isolated in blood, bile, ascites and preservation fluid cultures.
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